Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.

Abstract

PURPOSE A Phase I study in patients with advanced cancer was conducted to determine the safety, pharmacokinetics, and maximum tolerated dose of Triapine, a new, potent small-molecule inhibitor of ribonucleotide reductase. EXPERIMENTAL DESIGN Triapine was administered by 2-h i.v. infusion daily for 5 days. Courses were repeated every 4 weeks. The starting… (More)

Topics

6 Figures and Tables

Cite this paper

@article{Murren2003PhaseIA, title={Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.}, author={John R. Murren and Manuel R. Modiano and Caroline Ann Clairmont and Paula Lambert and Niramol Savaraj and Terry Doyle and Mario Sznol}, journal={Clinical cancer research : an official journal of the American Association for Cancer Research}, year={2003}, volume={9 11}, pages={4092-100} }